Cartesian Therapeutics Reports FY23 Net loss Of $(219.7)M Or $(1.66) Per Share Vs. Net Income Of $35.4M, Or $0.24 Per Share
Portfolio Pulse from Benzinga Newsdesk
Cartesian Therapeutics reported a FY23 net loss of $219.7 million, or $1.66 per share, a significant downturn from the previous year's net income of $35.4 million, or $0.24 per share.
March 07, 2024 | 12:23 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Cartesian Therapeutics, potentially associated with RNAC, reported a substantial FY23 net loss, contrasting sharply with last year's profit.
The drastic shift from a profitable year to a significant loss for Cartesian Therapeutics could negatively impact investor sentiment towards RNAC, assuming a direct association. Such financial results often lead to decreased investor confidence and potential sell-off, affecting the stock price negatively in the short term.
CONFIDENCE 75
IMPORTANCE 90
RELEVANCE 80